Filip Janku, MD, PhD, MD Anderson Cancer Center, TX, outlines safety and preliminary anti-tumor activity for THOR-707, a recombinant human IL-2 molecule, currently evaluating as a monotherapy and combined with pembrolizumab in the ongoing HAMMER Phase I/II clinical trial (NCT04009681). In patients with advanced or metastatic solid tumors, THOR-707 has demonstrated encouraging results, with initial efficacy and a tolerable safety profile. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.